The FDA has warned Sanofi about significant deviations from Current Good Manufacturing Practice regulations for active pharmaceutical ingredients.

Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a ...

Massachusetts. On Jan. 15, 2025, a warning letter was sent to Sanofi stating that FDA inspectors found irregularities with the facility's bioreactor, the vessel used to grow organisms and cells.

The U.S. Food and Drug Administration has warned the pharmaceutical company Sanofi about significant deviations from Current Good Manufacturing Practice for active pharmaceutical ingredients at their ...

Framingham-based retail parent TJX Cos. has purchased two office parcels on Framingham’s Speen Street for $24.3 million.

A Waltham biotech focused on cystic fibrosis and a Boston biotech led by serial founder Gary Glick are the first ...

20% of bioreactor runs at the Genzyme facility failed due to contamination or quality issues over 2.5 years. FDA identified 84 overdue deviation investigations, some exceeding 180 days ...

FRAMINGHAM — City officials announced the ... The MBTA Communities Act requires 177 communities in eastern Massachusetts to designate at least one zoning district that allows for multifamily ...

Real estate giant Skanska has laid out plans for the first phase of its Longwood Place Project, which includes bringing more ...

The owner of six sandwich shop franchises located in different Central Massachusetts communities will be required to pay back ...

Genzyme has fallen foul of the UK pharma industry code, for making misleading and disparaging claims about a competitor product. AstraZeneca has also been named in advertisements along with the ...